2023 Q4 Form 10-Q Financial Statement
#000095017023062011 Filed on November 09, 2023
Income Statement
Concept | 2023 Q4 | 2023 Q3 |
---|---|---|
Revenue | $36.28M | $11.99M |
YoY Change | 167.26% | -9.6% |
Cost Of Revenue | ||
YoY Change | ||
Gross Profit | ||
YoY Change | ||
Gross Profit Margin | ||
Selling, General & Admin | $116.5M | $29.40M |
YoY Change | 393.09% | 32.76% |
% of Gross Profit | ||
Research & Development | $435.1M | $113.7M |
YoY Change | 334.92% | 17.64% |
% of Gross Profit | ||
Depreciation & Amortization | $2.466M | $2.290M |
YoY Change | 21.42% | 17.44% |
% of Gross Profit | ||
Operating Expenses | $551.6M | $113.7M |
YoY Change | 346.03% | 17.64% |
Operating Profit | -$131.1M | |
YoY Change | 24.24% | |
Interest Expense | $34.20M | $8.880M |
YoY Change | 1523.88% | 7900.0% |
% of Operating Profit | ||
Other Income/Expense, Net | -$100.0K | $8.883M |
YoY Change | -98.16% | -215.38% |
Pretax Income | -$481.2M | -$122.2M |
YoY Change | 324.31% | 7.94% |
Income Tax | ||
% Of Pretax Income | ||
Net Earnings | -$481.2M | -$122.2M |
YoY Change | 324.31% | 7.94% |
Net Earnings / Revenue | -1326.51% | -1019.21% |
Basic Earnings Per Share | -$1.38 | |
Diluted Earnings Per Share | -$5.42 | -$1.38 |
COMMON SHARES | ||
Basic Shares Outstanding | 89.55M | 88.49M |
Diluted Shares Outstanding | 88.65M |
Balance Sheet
Concept | 2023 Q4 | 2023 Q3 |
---|---|---|
SHORT-TERM ASSETS | ||
Cash & Short-Term Investments | $912.2M | $854.8M |
YoY Change | -23.51% | 3.21% |
Cash & Equivalents | $226.7M | $168.0M |
Short-Term Investments | $685.5M | $686.8M |
Other Short-Term Assets | $49.65M | $32.20M |
YoY Change | 143.3% | 20.46% |
Inventory | ||
Prepaid Expenses | ||
Receivables | $36.46M | $6.491M |
Other Receivables | $0.00 | $0.00 |
Total Short-Term Assets | $998.3M | $893.5M |
YoY Change | -17.95% | 4.02% |
LONG-TERM ASSETS | ||
Property, Plant & Equipment | $32.76M | $33.80M |
YoY Change | 17.33% | 27.08% |
Goodwill | ||
YoY Change | ||
Intangibles | ||
YoY Change | ||
Long-Term Investments | $11.77M | $17.17M |
YoY Change | -63.75% | -57.19% |
Other Assets | $42.88M | $42.40M |
YoY Change | 5.81% | 14.63% |
Total Long-Term Assets | $302.6M | $349.9M |
YoY Change | -0.22% | 55.14% |
TOTAL ASSETS | ||
Total Short-Term Assets | $998.3M | $893.5M |
Total Long-Term Assets | $302.6M | $349.9M |
Total Assets | $1.301B | $1.243B |
YoY Change | -14.42% | 14.65% |
SHORT-TERM LIABILITIES | ||
YoY Change | ||
Accounts Payable | $7.452M | $3.553M |
YoY Change | 44.59% | -18.96% |
Accrued Expenses | $67.02M | $57.98M |
YoY Change | 10.09% | -0.69% |
Deferred Revenue | $22.14M | $13.35M |
YoY Change | -49.5% | -75.65% |
Short-Term Debt | $0.00 | $0.00 |
YoY Change | ||
Long-Term Debt Due | ||
YoY Change | ||
Total Short-Term Liabilities | $115.2M | $91.95M |
YoY Change | -8.97% | -29.88% |
LONG-TERM LIABILITIES | ||
Long-Term Debt | $0.00 | $0.00 |
YoY Change | ||
Other Long-Term Liabilities | $135.6M | $114.0M |
YoY Change | -14.16% | -11.2% |
Total Long-Term Liabilities | $135.6M | $114.0M |
YoY Change | -14.16% | -11.2% |
TOTAL LIABILITIES | ||
Total Short-Term Liabilities | $115.2M | $91.95M |
Total Long-Term Liabilities | $135.6M | $114.0M |
Total Liabilities | $250.8M | $205.9M |
YoY Change | -11.85% | -20.64% |
SHAREHOLDERS EQUITY | ||
Retained Earnings | -$1.658B | -$1.526B |
YoY Change | 40.88% | 43.47% |
Common Stock | $2.711B | $2.567B |
YoY Change | 12.01% | 35.25% |
Preferred Stock | ||
YoY Change | ||
Treasury Stock (at cost) | ||
YoY Change | ||
Treasury Stock Shares | ||
Shareholders Equity | $1.050B | $1.037B |
YoY Change | ||
Total Liabilities & Shareholders Equity | $1.301B | $1.243B |
YoY Change | -14.42% | 14.65% |
Cashflow Statement
Concept | 2023 Q4 | 2023 Q3 |
---|---|---|
OPERATING ACTIVITIES | ||
Net Income | -$481.2M | -$122.2M |
YoY Change | 324.31% | 7.94% |
Depreciation, Depletion And Amortization | $2.466M | $2.290M |
YoY Change | 21.42% | 17.44% |
Cash From Operating Activities | -$93.06M | -$101.4M |
YoY Change | 3.55% | 29.1% |
INVESTING ACTIVITIES | ||
Capital Expenditures | $1.515M | $4.340M |
YoY Change | -61.27% | -202.43% |
Acquisitions | ||
YoY Change | ||
Other Investing Activities | $47.46M | $83.83M |
YoY Change | -280.86% | 61.58% |
Cash From Investing Activities | $45.94M | $79.50M |
YoY Change | -252.37% | 66.87% |
FINANCING ACTIVITIES | ||
Cash Dividend Paid | ||
YoY Change | ||
Common Stock Issuance & Retirement, Net | ||
YoY Change | ||
Debt Paid & Issued, Net | ||
YoY Change | ||
Cash From Financing Activities | 106.5M | 19.10M |
YoY Change | -78.95% | -20.34% |
NET CHANGE | ||
Cash From Operating Activities | -93.06M | -101.4M |
Cash From Investing Activities | 45.94M | 79.50M |
Cash From Financing Activities | 106.5M | 19.10M |
Net Change In Cash | 59.37M | -2.780M |
YoY Change | -84.61% | -59.75% |
FREE CASH FLOW | ||
Cash From Operating Activities | -$93.06M | -$101.4M |
Capital Expenditures | $1.515M | $4.340M |
Free Cash Flow | -$94.57M | -$105.7M |
YoY Change | 0.84% | 42.31% |
Facts In Submission
Frame | Concept Type | Concept / XBRL Key | Value | Unit |
---|---|---|---|---|
dei |
Document Fiscal Period Focus
DocumentFiscalPeriodFocus
|
Q3 | ||
dei |
Current Fiscal Year End Date
CurrentFiscalYearEndDate
|
--12-31 | ||
dei |
Entity Central Index Key
EntityCentralIndexKey
|
0001652130 | ||
dei |
Amendment Flag
AmendmentFlag
|
false | ||
CY2023Q3 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
||
CY2022Q4 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
||
CY2023Q3 | us-gaap |
Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
|
http://fasb.org/us-gaap/2023#LicenseAndServiceMember | |
CY2022Q3 | us-gaap |
Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
|
http://fasb.org/us-gaap/2023#LicenseAndServiceMember | |
us-gaap |
Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
|
http://fasb.org/us-gaap/2023#LicenseAndServiceMember | ||
us-gaap |
Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
|
http://fasb.org/us-gaap/2023#LicenseAndServiceMember | ||
dei |
Document Type
DocumentType
|
10-Q | ||
dei |
Document Quarterly Report
DocumentQuarterlyReport
|
true | ||
dei |
Document Period End Date
DocumentPeriodEndDate
|
2023-09-30 | ||
dei |
Document Fiscal Year Focus
DocumentFiscalYearFocus
|
2023 | ||
dei |
Document Transition Report
DocumentTransitionReport
|
false | ||
dei |
Entity File Number
EntityFileNumber
|
001-37766 | ||
dei |
Entity Registrant Name
EntityRegistrantName
|
INTELLIA THERAPEUTICS, INC. | ||
dei |
Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
|
DE | ||
dei |
Entity Tax Identification Number
EntityTaxIdentificationNumber
|
36-4785571 | ||
dei |
Entity Address Address Line1
EntityAddressAddressLine1
|
40 Erie Street | ||
dei |
Entity Address Address Line2
EntityAddressAddressLine2
|
Suite 130 | ||
dei |
Entity Address City Or Town
EntityAddressCityOrTown
|
Cambridge | ||
dei |
Entity Address State Or Province
EntityAddressStateOrProvince
|
MA | ||
dei |
Entity Address Postal Zip Code
EntityAddressPostalZipCode
|
02139 | ||
dei |
City Area Code
CityAreaCode
|
857 | ||
dei |
Local Phone Number
LocalPhoneNumber
|
285-6200 | ||
dei |
Security12b Title
Security12bTitle
|
Common Stock, par value $0.0001 per share | ||
dei |
Trading Symbol
TradingSymbol
|
NTLA | ||
dei |
Security Exchange Name
SecurityExchangeName
|
NASDAQ | ||
dei |
Entity Current Reporting Status
EntityCurrentReportingStatus
|
Yes | ||
dei |
Entity Interactive Data Current
EntityInteractiveDataCurrent
|
Yes | ||
dei |
Entity Filer Category
EntityFilerCategory
|
Large Accelerated Filer | ||
dei |
Entity Small Business
EntitySmallBusiness
|
false | ||
dei |
Entity Emerging Growth Company
EntityEmergingGrowthCompany
|
false | ||
dei |
Entity Shell Company
EntityShellCompany
|
false | ||
CY2023Q4 | dei |
Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
|
89554891 | |
CY2023Q3 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
168027000 | |
CY2022Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
523506000 | |
CY2023Q3 | us-gaap |
Marketable Securities Current
MarketableSecuritiesCurrent
|
686761000 | |
CY2022Q4 | us-gaap |
Marketable Securities Current
MarketableSecuritiesCurrent
|
669116000 | |
CY2023Q3 | us-gaap |
Accounts Receivable Net Current
AccountsReceivableNetCurrent
|
6491000 | |
CY2022Q4 | us-gaap |
Accounts Receivable Net Current
AccountsReceivableNetCurrent
|
3768000 | |
CY2023Q3 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
32214000 | |
CY2022Q4 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
20407000 | |
CY2023Q3 | us-gaap |
Assets Current
AssetsCurrent
|
893493000 | |
CY2022Q4 | us-gaap |
Assets Current
AssetsCurrent
|
1216797000 | |
CY2023Q3 | us-gaap |
Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
|
137752000 | |
CY2022Q4 | us-gaap |
Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
|
69338000 | |
CY2023Q3 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
33800000 | |
CY2022Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
27921000 | |
CY2023Q3 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
118775000 | |
CY2022Q4 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
133076000 | |
CY2023Q3 | us-gaap |
Equity Method Investments
EquityMethodInvestments
|
17166000 | |
CY2022Q4 | us-gaap |
Equity Method Investments
EquityMethodInvestments
|
32455000 | |
CY2023Q3 | us-gaap |
Investments And Other Noncurrent Assets
InvestmentsAndOtherNoncurrentAssets
|
42363000 | |
CY2022Q4 | us-gaap |
Investments And Other Noncurrent Assets
InvestmentsAndOtherNoncurrentAssets
|
40527000 | |
CY2023Q3 | us-gaap |
Assets
Assets
|
1243349000 | |
CY2022Q4 | us-gaap |
Assets
Assets
|
1520114000 | |
CY2023Q3 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
3553000 | |
CY2022Q4 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
5154000 | |
CY2023Q3 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
57979000 | |
CY2022Q4 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
60876000 | |
CY2023Q3 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
17074000 | |
CY2022Q4 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
16685000 | |
CY2023Q3 | ntla |
Contract With Customer Liability Related Party Current
ContractWithCustomerLiabilityRelatedPartyCurrent
|
0 | |
CY2022Q4 | ntla |
Contract With Customer Liability Related Party Current
ContractWithCustomerLiabilityRelatedPartyCurrent
|
19900000 | |
CY2023Q3 | us-gaap |
Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
|
13347000 | |
CY2022Q4 | us-gaap |
Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
|
43839000 | |
CY2023Q3 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
91953000 | |
CY2022Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
126554000 | |
CY2023Q3 | us-gaap |
Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
|
12719000 | |
CY2022Q4 | us-gaap |
Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
|
19932000 | |
CY2023Q3 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
101263000 | |
CY2022Q4 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
114018000 | |
CY2023Q3 | us-gaap |
Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
|
0 | |
CY2022Q4 | us-gaap |
Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
|
24026000 | |
CY2023Q3 | us-gaap |
Liabilities
Liabilities
|
205935000 | |
CY2022Q4 | us-gaap |
Liabilities
Liabilities
|
284530000 | |
CY2023Q3 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.0001 | |
CY2022Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.0001 | |
CY2023Q3 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
240000000 | |
CY2022Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
120000000 | |
CY2023Q3 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
89097821 | |
CY2023Q3 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
89097821 | |
CY2022Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
87103007 | |
CY2022Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
87103007 | |
CY2023Q3 | us-gaap |
Common Stock Value
CommonStockValue
|
9000 | |
CY2022Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
9000 | |
CY2023Q3 | us-gaap |
Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
|
2567195000 | |
CY2022Q4 | us-gaap |
Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
|
2420223000 | |
CY2023Q3 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
-3572000 | |
CY2022Q4 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
-7461000 | |
CY2023Q3 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-1526218000 | |
CY2022Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-1177187000 | |
CY2023Q3 | us-gaap |
Stockholders Equity
StockholdersEquity
|
1037414000 | |
CY2022Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
1235584000 | |
CY2023Q3 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
1243349000 | |
CY2022Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
1520114000 | |
CY2023Q3 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
11992000 | |
CY2022Q3 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
13266000 | |
us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
38192000 | ||
us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
38548000 | ||
CY2023Q3 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
113696000 | |
CY2022Q3 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
96651000 | |
us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
326088000 | ||
us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
319945000 | ||
CY2023Q3 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
29403000 | |
CY2022Q3 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
22145000 | |
us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
87503000 | ||
us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
66680000 | ||
CY2023Q3 | us-gaap |
Costs And Expenses
CostsAndExpenses
|
143099000 | |
CY2022Q3 | us-gaap |
Costs And Expenses
CostsAndExpenses
|
118796000 | |
us-gaap |
Costs And Expenses
CostsAndExpenses
|
413591000 | ||
us-gaap |
Costs And Expenses
CostsAndExpenses
|
386625000 | ||
CY2023Q3 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-131107000 | |
CY2022Q3 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-105530000 | |
us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-375399000 | ||
us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-348077000 | ||
CY2023Q3 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
12740000 | |
CY2022Q3 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
1945000 | |
us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
37373000 | ||
us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
3188000 | ||
CY2023Q3 | us-gaap |
Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
|
-3857000 | |
CY2022Q3 | us-gaap |
Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
|
-1834000 | |
us-gaap |
Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
|
-10905000 | ||
us-gaap |
Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
|
-7831000 | ||
CY2023Q3 | us-gaap |
Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
|
0 | |
CY2022Q3 | us-gaap |
Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
|
7810000 | |
us-gaap |
Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
|
100000 | ||
us-gaap |
Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
|
8059000 | ||
CY2023Q3 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
8883000 | |
CY2022Q3 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
-7699000 | |
us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
26368000 | ||
us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
-12702000 | ||
CY2023Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-122224000 | |
CY2022Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-113229000 | |
us-gaap |
Net Income Loss
NetIncomeLoss
|
-349031000 | ||
us-gaap |
Net Income Loss
NetIncomeLoss
|
-360779000 | ||
CY2023Q3 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-1.38 | |
CY2023Q3 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-1.38 | |
CY2022Q3 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-1.49 | |
CY2022Q3 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-1.49 | |
us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-3.96 | ||
us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-3.96 | ||
us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-4.78 | ||
us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-4.78 | ||
CY2023Q3 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
88645000 | |
CY2023Q3 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
88645000 | |
CY2022Q3 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
76047000 | |
CY2022Q3 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
76047000 | |
us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
88204000 | ||
us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
88204000 | ||
us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
75543000 | ||
us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
75543000 | ||
CY2023Q3 | us-gaap |
Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
|
142000 | |
CY2022Q3 | us-gaap |
Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
|
991000 | |
us-gaap |
Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
|
1649000 | ||
us-gaap |
Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
|
-5069000 | ||
CY2023Q3 | us-gaap |
Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Investment Transferred From Available For Sale To Equity Method Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAociForInvestmentTransferredFromAvailableForSaleToEquityMethodTax
|
154000 | |
CY2022Q3 | us-gaap |
Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Investment Transferred From Available For Sale To Equity Method Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAociForInvestmentTransferredFromAvailableForSaleToEquityMethodTax
|
-805000 | |
us-gaap |
Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Investment Transferred From Available For Sale To Equity Method Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAociForInvestmentTransferredFromAvailableForSaleToEquityMethodTax
|
2240000 | ||
us-gaap |
Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Investment Transferred From Available For Sale To Equity Method Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAociForInvestmentTransferredFromAvailableForSaleToEquityMethodTax
|
-1667000 | ||
CY2023Q3 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-121928000 | |
CY2022Q3 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-113043000 | |
us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-345142000 | ||
us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-367515000 | ||
CY2023Q3 | ntla |
Revenue From Related Party
RevenueFromRelatedParty
|
1946000 | |
CY2022Q3 | ntla |
Revenue From Related Party
RevenueFromRelatedParty
|
4414000 | |
ntla |
Revenue From Related Party
RevenueFromRelatedParty
|
12673000 | ||
ntla |
Revenue From Related Party
RevenueFromRelatedParty
|
15612000 | ||
us-gaap |
Profit Loss
ProfitLoss
|
-349031000 | ||
us-gaap |
Profit Loss
ProfitLoss
|
-360779000 | ||
us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
6510000 | ||
us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
5541000 | ||
us-gaap |
Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
|
-5000 | ||
us-gaap |
Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
|
162000 | ||
us-gaap |
Share Based Compensation
ShareBasedCompensation
|
99007000 | ||
us-gaap |
Share Based Compensation
ShareBasedCompensation
|
66774000 | ||
us-gaap |
Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
|
19590000 | ||
us-gaap |
Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
|
-5252000 | ||
us-gaap |
Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
|
-10905000 | ||
us-gaap |
Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
|
-7831000 | ||
us-gaap |
Equity Method Investment Sold Carrying Amount
EquityMethodInvestmentSoldCarryingAmount
|
6624000 | ||
us-gaap |
Equity Method Investment Sold Carrying Amount
EquityMethodInvestmentSoldCarryingAmount
|
8530000 | ||
us-gaap |
Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
|
100000 | ||
us-gaap |
Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
|
8059000 | ||
ntla |
In Process Research And Development Charge
InProcessResearchAndDevelopmentCharge
|
0 | ||
ntla |
In Process Research And Development Charge
InProcessResearchAndDevelopmentCharge
|
55990000 | ||
us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
2723000 | ||
us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
1992000 | ||
us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
11806000 | ||
us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
228000 | ||
ntla |
Increase Decrease In Operating Right Of Use Assets
IncreaseDecreaseInOperatingRightOfUseAssets
|
-14148000 | ||
ntla |
Increase Decrease In Operating Right Of Use Assets
IncreaseDecreaseInOperatingRightOfUseAssets
|
-8516000 | ||
us-gaap |
Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
|
836000 | ||
us-gaap |
Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
|
982000 | ||
us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
-1419000 | ||
us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
-5334000 | ||
us-gaap |
Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
|
-3008000 | ||
us-gaap |
Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
|
12852000 | ||
us-gaap |
Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
|
-37705000 | ||
us-gaap |
Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
|
-46739000 | ||
ntla |
Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
|
-12213000 | ||
ntla |
Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
|
-6547000 | ||
us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-301032000 | ||
us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-243418000 | ||
us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
12465000 | ||
us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
9646000 | ||
us-gaap |
Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
|
754689000 | ||
us-gaap |
Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
|
192598000 | ||
us-gaap |
Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
|
689868000 | ||
us-gaap |
Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
|
437387000 | ||
us-gaap |
Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
|
0 | ||
us-gaap |
Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
|
150000 | ||
us-gaap |
Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
|
287000 | ||
us-gaap |
Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
|
0 | ||
us-gaap |
Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
|
44832000 | ||
us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-77286000 | ||
us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
190461000 | ||
us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
5604000 | ||
us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
13984000 | ||
us-gaap |
Proceeds From Stock Plans
ProceedsFromStockPlans
|
2051000 | ||
us-gaap |
Proceeds From Stock Plans
ProceedsFromStockPlans
|
1068000 | ||
us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
23839000 | ||
us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
77192000 | ||
us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
-354479000 | ||
us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
24235000 | ||
CY2022Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
535463000 | |
CY2021Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
125486000 | |
CY2023Q3 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
180984000 | |
CY2022Q3 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
149721000 | |
CY2023Q3 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
168027000 | |
CY2022Q3 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
141194000 | |
CY2023Q3 | us-gaap |
Restricted Cash Equivalents
RestrictedCashEquivalents
|
12957000 | |
CY2022Q3 | us-gaap |
Restricted Cash Equivalents
RestrictedCashEquivalents
|
8527000 | |
CY2023Q3 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
180984000 | |
CY2022Q3 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
149721000 | |
us-gaap |
Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
|
1552000 | ||
us-gaap |
Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
|
2180000 | ||
CY2023Q3 | ntla |
Shares Issued For Rewrite Contingent Consideration
SharesIssuedForRewriteContingentConsideration
|
24126000 | |
CY2022Q3 | ntla |
Shares Issued For Rewrite Contingent Consideration
SharesIssuedForRewriteContingentConsideration
|
0 | |
ntla |
Right Of Use Assets Acquired Under Operating Lease
RightOfUseAssetsAcquiredUnderOperatingLease
|
0 | ||
ntla |
Right Of Use Assets Acquired Under Operating Lease
RightOfUseAssetsAcquiredUnderOperatingLease
|
30663000 | ||
CY2023Q3 | us-gaap |
Asset Acquisition Contingent Consideration Liability
AssetAcquisitionContingentConsiderationLiability
|
0 | |
CY2022Q3 | us-gaap |
Asset Acquisition Contingent Consideration Liability
AssetAcquisitionContingentConsiderationLiability
|
10541000 | |
ntla |
Proceeds From At The Market Offerings Unpaid At Period End
ProceedsFromAtTheMarketOfferingsUnpaidAtPeriodEnd
|
0 | ||
ntla |
Proceeds From At The Market Offerings Unpaid At Period End
ProceedsFromAtTheMarketOfferingsUnpaidAtPeriodEnd
|
8255000 | ||
ntla |
Non Cash Trade In Of Property And Equipment
NonCashTradeInOfPropertyAndEquipment
|
0 | ||
ntla |
Non Cash Trade In Of Property And Equipment
NonCashTradeInOfPropertyAndEquipment
|
200000 | ||
CY2023Q3 | us-gaap |
Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
|
826633000 | |
CY2023Q3 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
|
47000 | |
CY2023Q3 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
|
2167000 | |
CY2023Q3 | us-gaap |
Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
|
824513000 | |
CY2022Q4 | us-gaap |
Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
|
742215000 | |
CY2022Q4 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
|
62000 | |
CY2022Q4 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
|
3823000 | |
CY2022Q4 | us-gaap |
Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
|
738454000 | |
us-gaap |
Marketable Securities Realized Gain Loss
MarketableSecuritiesRealizedGainLoss
|
0 | ||
CY2022 | us-gaap |
Marketable Securities Realized Gain Loss
MarketableSecuritiesRealizedGainLoss
|
0 | |
ntla |
Research Milestone Payments
ResearchMilestonePayments
|
25000000 | ||
CY2022Q4 | us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
|
24026000 | |
CY2023Q3 | us-gaap |
Contingent Consideration Classified As Equity Fair Value Disclosure
ContingentConsiderationClassifiedAsEquityFairValueDisclosure
|
100000 | |
us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
|
-24126000 | ||
CY2023Q3 | us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
|
0 | |
CY2022 | ntla |
Discount Rate
DiscountRate
|
0.101 | |
CY2022 | ntla |
Probability Of Achievement
ProbabilityOfAchievement
|
1 | |
CY2022 | ntla |
Projected Year Of Achievement
ProjectedYearOfAchievement
|
2023 | |
CY2023Q3 | ntla |
Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
|
24241000 | |
CY2022Q4 | ntla |
Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
|
32684000 | |
CY2023Q3 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
21006000 | |
CY2022Q4 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
21778000 | |
CY2023Q3 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
1649000 | |
CY2022Q4 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
1457000 | |
CY2023Q3 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
11083000 | |
CY2022Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
4957000 | |
CY2023Q3 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
57979000 | |
CY2022Q4 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
60876000 | |
CY2022Q4 | us-gaap |
Accounts Receivable Net Current
AccountsReceivableNetCurrent
|
3768000 | |
ntla |
Increase In Accounts Receivables
IncreaseInAccountsReceivables
|
15287000 | ||
ntla |
Decrease In Accounts Receivables
DecreaseInAccountsReceivables
|
12564000 | ||
CY2023Q3 | us-gaap |
Accounts Receivable Net Current
AccountsReceivableNetCurrent
|
6491000 | |
CY2022Q4 | us-gaap |
Contract With Customer Liability
ContractWithCustomerLiability
|
63771000 | |
us-gaap |
Contract With Customer Liability Change In Timeframe Performance Obligation Satisfied Revenue Recognized
ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized
|
-37705000 | ||
CY2023Q3 | us-gaap |
Contract With Customer Liability
ContractWithCustomerLiability
|
26066000 | |
CY2021Q4 | us-gaap |
Accounts Receivable Net Current
AccountsReceivableNetCurrent
|
2031000 | |
ntla |
Increase In Accounts Receivables
IncreaseInAccountsReceivables
|
8678000 | ||
ntla |
Decrease In Accounts Receivables
DecreaseInAccountsReceivables
|
6686000 | ||
CY2022Q3 | us-gaap |
Accounts Receivable Net Current
AccountsReceivableNetCurrent
|
4023000 | |
CY2021Q4 | us-gaap |
Contract With Customer Liability
ContractWithCustomerLiability
|
127235000 | |
us-gaap |
Contract With Customer Liability Change In Timeframe Performance Obligation Satisfied Revenue Recognized
ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized
|
-46739000 | ||
CY2022Q3 | us-gaap |
Contract With Customer Liability
ContractWithCustomerLiability
|
80496000 | |
us-gaap |
Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
|
31081000 | ||
us-gaap |
Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
|
38208000 | ||
CY2023Q3 | us-gaap |
Capitalized Contract Cost Gross
CapitalizedContractCostGross
|
0 | |
ntla |
Business Combination Upfront Cash Consideration
BusinessCombinationUpfrontCashConsideration
|
43730000 | ||
ntla |
Business Combination Research Contingent Consideration Liabilities
BusinessCombinationResearchContingentConsiderationLiabilities
|
10541000 | ||
ntla |
Business Acquisition Cost Of Acquired Entity Transaction Cost
BusinessAcquisitionCostOfAcquiredEntityTransactionCost
|
1838000 | ||
us-gaap |
Business Combination Consideration Transferred1
BusinessCombinationConsiderationTransferred1
|
56109000 | ||
CY2023Q3 | ntla |
Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed In Process Research And Development
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment
|
55990000 | |
CY2023Q3 | us-gaap |
Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Cash And Equivalents
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
|
287000 | |
CY2023Q3 | us-gaap |
Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Assets
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets
|
153000 | |
CY2023Q3 | us-gaap |
Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Liabilities
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities
|
321000 | |
CY2023Q3 | ntla |
Business Combination Transaction Price
BusinessCombinationTransactionPrice
|
56109000 | |
CY2023Q3 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
35352000 | |
CY2022Q3 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
25215000 | |
us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
99007000 | ||
us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
66774000 | ||
CY2022Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
|
1941379 | |
CY2022Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
|
70.70 | |
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
|
2774271 | ||
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
42.36 | ||
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
|
597610 | ||
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
|
68.31 | ||
ntla |
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Cancelled In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod
|
193503 | ||
ntla |
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Cancelled In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAverageGrantDateFairValue
|
49.7 | ||
CY2023Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
|
3924537 | |
CY2023Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
|
52.07 | |
CY2023Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
40.75 | |
CY2022Q1 | ntla |
Number Of Tranches
NumberOfTranches
|
2 | |
CY2023Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
39.14 | |
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
42.36 | ||
CY2023Q3 | ntla |
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value Amount
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValueAmount
|
4200000 | |
ntla |
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value Amount
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValueAmount
|
22500000 | ||
CY2022Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
55.59 | |
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
72.48 | ||
CY2022Q3 | ntla |
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value Amount
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValueAmount
|
100000 | |
ntla |
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value Amount
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValueAmount
|
8000000 | ||
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
28.92 | ||
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
57.23 | ||
CY2023Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
|
0 | |
CY2022Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
|
0 | |
CY2023Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
|
4800000 | |
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
|
6600000 | ||
CY2022Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
|
1400000 | |
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
|
41800000 | ||
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
|
0.044 | ||
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
|
0.019 | ||
us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
|
P6Y | ||
us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
|
P5Y10M24D | ||
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
|
0.787 | ||
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
|
0.762 | ||
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
|
0 | ||
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
|
0 | ||
CY2022Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
5471675 | |
CY2022Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
49.86 | |
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
569821 | ||
us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
|
41 | ||
us-gaap |
Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
|
319847 | ||
us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
|
17.52 | ||
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
|
130474 | ||
us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
|
80.2 | ||
CY2023Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
5591175 | |
CY2023Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
50.1 | |
us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
|
P6Y10M13D | ||
CY2023Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
|
39821000 | |
CY2023Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
|
3846015 | |
CY2023Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
|
42.52 | |
us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
|
P6Y3M18D | ||
us-gaap |
Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
|
6600000 | ||
CY2023Q3 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
|
36370000 | |
CY2023Q3 | us-gaap |
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
|
69200000 | |
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
|
P1Y7M17D | ||
CY2023Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-122224000 | |
CY2022Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-113229000 | |
us-gaap |
Net Income Loss
NetIncomeLoss
|
-349031000 | ||
us-gaap |
Net Income Loss
NetIncomeLoss
|
-360779000 | ||
CY2023Q3 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
88645000 | |
CY2023Q3 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
88645000 | |
CY2022Q3 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
76047000 | |
CY2022Q3 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
76047000 | |
us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
88204000 | ||
us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
88204000 | ||
us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
75543000 | ||
us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
75543000 | ||
CY2023Q3 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-1.38 | |
CY2023Q3 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-1.38 | |
CY2022Q3 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-1.49 | |
CY2022Q3 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-1.49 | |
us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-3.96 | ||
us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-3.96 | ||
us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-4.78 | ||
us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-4.78 | ||
us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
9516000 | ||
CY2023Q3 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
9516000 | |
us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
7476000 | ||
CY2022Q3 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
7476000 | |
CY2023Q1 | us-gaap |
Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
|
62000 | |
CY2023Q2 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
465000 | |
CY2023Q2 | us-gaap |
Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
|
2051000 | |
CY2023Q2 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
36400000 | |
CY2023Q2 | us-gaap |
Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
|
-1482000 | |
CY2023Q2 | us-gaap |
Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Investment Transferred From Available For Sale To Equity Method Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAociForInvestmentTransferredFromAvailableForSaleToEquityMethodTax
|
292000 | |
CY2023Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-123681000 | |
CY2023Q2 | us-gaap |
Stockholders Equity
StockholdersEquity
|
1104888000 | |
CY2023Q3 | us-gaap |
Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
|
81000 | |
CY2023Q3 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
4384000 | |
CY2023Q3 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
35352000 | |
CY2023Q3 | us-gaap |
Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
|
142000 | |
CY2023Q3 | us-gaap |
Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Investment Transferred From Available For Sale To Equity Method Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAociForInvestmentTransferredFromAvailableForSaleToEquityMethodTax
|
154000 | |
CY2023Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-122224000 | |
CY2023Q3 | us-gaap |
Stockholders Equity
StockholdersEquity
|
1037414000 | |
CY2021Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
1040244000 | |
CY2022Q1 | us-gaap |
Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
|
164000 | |
CY2022Q1 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
8435000 | |
CY2022Q1 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
18491000 | |
CY2022Q1 | us-gaap |
Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
|
-5128000 | |
CY2022Q1 | us-gaap |
Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Investment Transferred From Available For Sale To Equity Method Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAociForInvestmentTransferredFromAvailableForSaleToEquityMethodTax
|
-302000 | |
CY2022Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-146872000 | |
CY2022Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
953754000 | |
CY2022Q2 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
4827000 | |
CY2022Q2 | us-gaap |
Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
|
1068000 | |
CY2022Q2 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
23068000 | |
CY2022Q2 | us-gaap |
Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
|
-932000 | |
CY2022Q2 | us-gaap |
Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Investment Transferred From Available For Sale To Equity Method Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAociForInvestmentTransferredFromAvailableForSaleToEquityMethodTax
|
-560000 | |
CY2022Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-100678000 | |
CY2022Q2 | us-gaap |
Stockholders Equity
StockholdersEquity
|
880547000 | |
CY2022Q3 | us-gaap |
Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
|
54000 | |
CY2022Q3 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
722000 | |
CY2022Q3 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
25215000 | |
CY2022Q3 | us-gaap |
Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
|
-991000 | |
CY2022Q3 | us-gaap |
Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Investment Transferred From Available For Sale To Equity Method Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAociForInvestmentTransferredFromAvailableForSaleToEquityMethodTax
|
-805000 | |
CY2022Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-113229000 | |
CY2022Q3 | us-gaap |
Stockholders Equity
StockholdersEquity
|
824951000 | |
CY2022Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
120000000 | |
CY2023Q3 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
240000000 | |
CY2023Q3 | us-gaap |
Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
|
1000000 |